Stock comparison
Grifols
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GRFS
Grifols
Market cap
$6.89B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.13B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GRFS | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 59D | 79B | HALO |
| Benjamin Graham | 54C | 83A | HALO |
| Philip Fisher | 50C | 65B | HALO |
| Peter Lynch | 44D | 53D | HALO |
| Joel Greenblatt | 26F | 40D | HALO |
| Charlie Munger | 44D | 80C | HALO |
| Terry Smith | 47D | 84A | HALO |
Side-by-side metrics
| Metric | GRFS | HALO |
|---|---|---|
| Market cap | $6.89B | $8.13B |
| P/E (TTM) | 14.9x | 24.0x |
| EV/EBIT | 12.8x | 10.2x |
| ROIC (TTM) | 5.49% | 23.65% |
| Gross margin | 37.68% | 81.24% |
| Net margin | 5.58% | 23.13% |
| Revenue CAGR 5y | 10.02% | 33.23% |
| EPS CAGR 5y | 20.54% | -1.98% |
| Debt / Equity | 1.8x | 1.0x |
| Dividend yield | 1.65% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GRFS leads on
- EPS CAGR 5y20.54%vs -1.98%+110%
- Dividend yield1.65%vs 0.0%+100%
- P/E (TTM)14.9xvs 24.0x+38%
HALO leads on
- ROIC (TTM)23.65%vs 5.49%+77%
- Net margin23.13%vs 5.58%+76%
- Revenue CAGR 5y33.23%vs 10.02%+70%
- Gross margin81.24%vs 37.68%+54%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.